Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
¹⁸F-FLT-PET for Response to Radiotherapy in Soft Tissue Sarcoma
NCT03613259Phase 1Withdrawn
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Jun 2020
- Primary completion
- Jun 2022
01
Overview
Phase 1, open-label, single-arm trial, sponsored by OHSU Knight Cancer Institute. Primary endpoint: Change in Fluorothymidine F-18 mean standardized uptake value. Planned start Jun 2020; status: withdrawn.
Beyond the preview
Go deeper on NCT03613259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03613259.